Pharis Mohideen - DBV Technologies Chief Medical Officer
| DBV Stock | EUR 0.65 0.05 8.33% |
Executive
Dr. Pharis Mohideen, M.D., was appointed as Chief Medical Officer of DV Technologies SA since June 26, 2019. He has nearly two decades of industry experience. He most recently served as CMO for Millendo Therapeutics, Inc., where he created and executed clinical development and regulatory strategies. At Millendo, he helped to expand the clinical pipeline from a single indication to multiple indications and was involved with initiating new clinical trials in Cushings syndrome, congenital adrenal hyperplasia, PraderWilli syndrome and polycystic ovary syndrome. Previously, Dr. Mohideen was Vice President of Clinical Development at Shionogi Inc., a global pharmaceutical company, where he designed and helped lead the company through its first full Phase III development program outside of Japan and was a core member of the team that gained FDA approval of ospemifene . Prior to Shionogi, Dr. Mohideen served as Executive Medical Director, Oncology at Novartis International AG, where he was responsible for leading all clinical development and registration activities for three key compounds including pasireotide . Additionally, he was the registration lead for vildagliptin for the treatment of Type 2 diabetes and helped lead the EMA submission and approval in this indication since 2019.
| Age | 58 |
| Tenure | 5 years |
| Professional Marks | Ph.D |
| Phone | 33 1 55 42 78 78 |
| Web | https://www.dbv-technologies.com |
Pharis Mohideen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Pharis Mohideen against DBV Technologies stock is an integral part of due diligence when investing in DBV Technologies. Pharis Mohideen insider activity provides valuable insight into whether DBV Technologies is net buyers or sellers over its current business cycle. Note, DBV Technologies insiders must abide by specific rules, including filing SEC forms every time they buy or sell DBV Technologies'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Pharis Mohideen few days ago Disposition of 342 shares by Pharis Mohideen of DBV Technologies at 0.53 subject to Rule 16b-3 | ||
Pharis Mohideen over three months ago Acquisition by Pharis Mohideen of 115000 shares of DBV Technologies at 3.07 subject to Rule 16b-3 | ||
Pharis Mohideen over six months ago Disposition of 660 shares by Pharis Mohideen of DBV Technologies at 1.36 subject to Rule 16b-3 | ||
Pharis Mohideen over six months ago Sale by Pharis Mohideen of 2245 shares of DBV Technologies |
DBV Technologies Management Efficiency
The company has return on total asset (ROA) of (0.2178) % which means that it has lost $0.2178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4299) %, meaning that it generated substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.43 | |||
| Return On Asset | -0.22 |
DBV Technologies Leadership Team
Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wence Agbotounou, Chief Clinical Trial Officer | ||
| Viviane Monges, Non-Executive Independent Director | ||
| Caroline Daniere, Chief Human Resource Officer | ||
| Claire Giraut, Non-Executive Independent Director | ||
| Adam Slatter, Chief Quality Officer | ||
| Daniel Tass, CEO Director | ||
| Daniel Soland, Non-Executive Independent Director | ||
| Julie ONeill, Non-Executive Director | ||
| Hugh Sampson, Chief Scientific Officer | ||
| Pascal Wotling, Chief Technical Operations Officer | ||
| Ramzi Benamar, Chief Financial Officer | ||
| Lucie Mondoulet, Director of Research | ||
| Anne Pollak, Head Relations | ||
| Michele Robertson, Chief Legal Officer | ||
| MarieCatherine Therene, Deputy Chief Executive Officer and Responsible Pharmacist | ||
| Joseph Becker, VP Communications | ||
| Sbastien Robitaille, Chief Officer | ||
| Daniel Tasse, Chief Executive Officer, Director | ||
| Michael Goller, Non-Executive Director | ||
| Sebastien Robitaille, Chief Financial Officer | ||
| Torbjorn Bjerke, Non-Executive Independent Director | ||
| Pharis Mohideen, Chief Medical Officer | ||
| Kevin Trapp, Chief Commercial Officer | ||
| Mailys Ferrere, Non-Executive Director | ||
| Michel Rosen, Non-Executive Independent Chairman of the Board |
DBV Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (8.04) % | |||
| Current Valuation | 51.36 M | |||
| Shares Outstanding | 93.97 M | |||
| Shares Owned By Insiders | 6.50 % | |||
| Shares Owned By Institutions | 33.06 % | |||
| Price To Earning | 7.49 X | |||
| Price To Book | 1.24 X | |||
| Price To Sales | 28.00 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in DBV Stock
DBV Technologies financial ratios help investors to determine whether DBV Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DBV with respect to the benefits of owning DBV Technologies security.